Drospirenone: A novel progestin

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 7, 2007, Pages 989-999

  Rapkin, Andrea J ^a   Winer, Sharon A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aldosterone antagonist; Drospirenone; Hormone replacement; Oral contraceptive pills; Premenstrual dysphoric disorder

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYPROTERONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ENALAPRIL MALEATE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; HYDROXYPROGESTERONE; IBUPROFEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NANDROLONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SPIRONOLACTONE; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YAZ; ALDOSTERONE ANTAGONIST; ANDROSTANE DERIVATIVE; ANTIANDROGEN; PROGESTERONE DERIVATIVE;

ACNE; ACNE VULGARIS; ARTICLE; BLEEDING; BLOOD PRESSURE; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERKALEMIA; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MONOTHERAPY; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM; VULVA DISEASE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; DRUG COMBINATION; ESTROGEN THERAPY; FEMALE; REVIEW;

ACNE VULGARIS; ALDOSTERONE ANTAGONISTS; ANDROGEN ANTAGONISTS; ANDROSTENES; ANIMALS; CLINICAL TRIALS; CONTRACEPTIVES, ORAL, COMBINED; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ETHINYL ESTRADIOL; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; PROGESTERONE CONGENERS;

EID: 34249691244     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.7.989     Document Type: Article

References (71)

1. ROSENBERG MJ, WAUGH MS: Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol. (1998) 179(3 Pt 1):577-582.
2. MISHELL DR: Noncontraceptive health benefits of oral steroidal contraceptives. Am. J. Obstet. Gynecol. (1982) 142(6 Pt 2):809-816.
3. THE PRACTICE COMMITTEE OF THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE: Estrogen and progestogen therapy in postmenopausal women. Fertil. Steril. (2006) 86(5):75-88.
4. MOSHER W: Use of contraception and use of family planning services in the United States: 1982-2002. Advance data for vital and health statistics: no. 350. National Center for Health Statistics, Hyattsville, Maryland (2004).
5. MISHELL DR: Prevention of unplanned pregnancy: current status. J. Reprod. Med. (2000) 45:867-871.
6. ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
7. LOBO RA, STANCZYK FZ: New knowledge in the physiology of hormonal contraceptives. Am. J. Obstet. Gynecol. (1994) 170(5 Pt 2):1499-1507.
8. SPEROFF L, GLASS RH, KASE NG: Steroid contraception. In: Clinical Gynecologic Endocrinology and Infertility. Williams and Wilkins, Baltimore (1999).
9. SITRUK-WARE R: Pharmacology of different progestogens: the special case of drospirenone. Climacteric (2005) 8(Suppl. 3):4-12.
10. SITRUK-WARE R: Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause (2002) 9(1):6-15.
11. KRATTENMACHER R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception (2000) 62:29-38.
12. RUBIG A: Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric (2003) 6(3):49-54.
13. MUHN P, FUHRMANN U, FRITZEMEIER KH et al.: Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Ann. NY Acad. Sci. (1995) 761:311-335.
14. KEAM SJ, WAGSTAFF AJ: Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat. Endocrinol. (2003) 2(1):49-70.
15. ARCHER D, THORNEYCROFT I, FOEGH M et al.: Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause (2005) 12(6):716-727.
16. SHURMANN R, HOLLER T, BENDAN: Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo controlled study of the safety and efficacy of the three dose regimens. Climateric (2004) 7:189-196.
17. WARMING L, RAVN P, NIELSEN T et al.: Safety and efficacy of drospirenone used in a continuous combination with 17 β-estradiol for prevention of postmenopausal osceoporosis. Climateric (2004) 7:103-111.
18. SHULMAN LP: A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted wich medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. J. Womens Health (2006) 15(5):584-590.
19. FUHRMANN U, KRATTENMACHER R, SLATER EP, FRITZEME IER KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception (1996) 54(4):243-251.
20. OELKERS WK: Effects of estrogens and progestogens on the rennin-aldosterone system and blood pressure. Steroids (1996) 61(4):166-171.
21. OELKERS W: Drospirenone-a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur. J. Contracept. Reprod. Health Care (2000) 5(3):17-24.
22. OELKERS W, FOIDART JM, DOMBROVICZ N, WELTER A, HEITHECKER RE: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol Metab. (1995) 80:1816-1821.
23. ELGER W, BEIER S, POLLOW K, GARFIELD R, SHI SQ, HILLISCH A: Conception and pharmacodynamic profile of drospirenone. Steroids (2003) 68(10-13):891-905.
24. HARDMAN JG, LIMBIRDLE, GILMAN AG: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill, New York (2001):1610
25. MISHELL DR Jr: Cardiovascular risks: perception versus reality. Contraception (1999) 59(1 Suppl.):21S-24S.
26. GASPARD U, SCHEEN A, ENDRIKAT J et al.: A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception (2003) 67(6):423-429.
27. OELKERS WH: Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climateric (2005) 8(Suppl. 3):19-27.
28. HUBER J, FOIDART JM, WUTTKE W et al.: Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care (2000) 5(1):25-34.
29. MUHN P, KRATTENMACHER R, BEIER S, ELGER W, SCHILLINGER E: Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception (1995) 51:99-110.
30. BLODE H, WUTTKE W, LOOCK W, ROLL C, HEITHECKER R: A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur. J. Contracept. Reprod. Health Care (2000) 5(4):256-264.
31. OELKERS W, HELMERHORST FM, WUTTKE W, HEITHECKER R: Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. (2000) 14(3):204-213.
32. LUDICKE F, JOHANNISSON E, HELMERHORST FM, CAMPANA A, FOIDART J, HEITHECKER R: Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil. Steril. (2001) 76(1):102-107.
33. ROSENBAUM P, SCHMIDT W, HELMERHORST FM et al.: Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur. J. Contracept. Reprod. Health Care (2000) 5(1):16-24.
34. PARSEY KS, PONG A: An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception (2000) 61(2):105-111.
35. AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS: Premenstrual syndrome. ACOG Practice Bulletin. (2000): Number 15.
36. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th edn, text revision. American Psychiatric Association, Washington, DC (2000).
37. BORENSTEIN JE, DEAN BB, ENDICOTT J et al.: Health and economic impact of the premenstrual syndrome. J. Reprod. Med. (2003) 48(7):515-524.
38. WINER SA, RAPKIN AJ: Premenstrual disorders: prevalence, etiology and impact. J. Reprod. Med. (2006) 51(4 Suppl.):229-347.
39. STEINER M, PEBALSTEIN T: Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J. Clin. Psychiatry (2000) 61:17-21.
40. BACKSTROM T, ANDERSSON A, ANDREE L et al.: Pathogenesis in menstrual cycle-linked disorders. Ann. NY Acad. Sci. (2003) 1007:42-53.
41. JOFFEE H, COHEN LS, HARLOW BL: Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am. J. Obstet. Gynecol. (2003) 189:1523-1530.
42. FOIDART JM, WUTTKE W, BOUW GM, GERLINGER C, HEITHECKER R: A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care (2000) 5(2):124-134.
43. SANGTHAWAN M, TANEEPANICHSKUL S: A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception (2005) 71(1):1-7.
44. APTER D, BORSOS A, BAUMGARTNER W et al.: Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Health Care (2003) 8(1):37-51.
45. BROWN C, LING F, WAN J: A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J. Reprod. Med. (2002) 47(1):14-22.
46. FREEMAN EW, KROLL R, RAPKIN A et al.: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J. Womens Health Gend. Based Med. (2001) 10(6):561-569.
47. SILLEM M, SCHNEIDEREIT R, HEITHECKER R, MUECK AO: Use of an oral contraceptive containing drospirenone in an extended regimen. Eur. J. Contracept. Reprod. Health Care (2003) 8(3):162-169.
48. WILLIS SA, KUEHL TJ, SPIEKERMAN AM, SULAK PJ: Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception (2006) 74(2):100-103.
49. BACHMANN G, SULAK PJ, SAMPSON-LANDERS C, BENDA N, MARR J: Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception (2004) 70(3):191-198.
50. YONKERS KA, BROWN C, PEARLSTEIN TB, FOEGH M, SAMPSON-LANDERS C, RAPKIN A: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. (2005) 106(3):492-501.
51. PEARLSTEIN TB, BACHMANN GA, ZACUR HA, YONKERS KA: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception (2005) 72(6):414-421.
52. VAN VLOTEN WA, VAN HASELEN CW, VAN ZUUREN EJ, GERLINGER C, HEITHECKER R: The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis (2002) 69(4):2-15.
53. THORNEYCROFT H, GOLLNICK H, SCHELLSCHMIDT 1: Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis (2004) 74(2):123-130.
54. SITRUK-WARE R: New progestogens: a review of their effects in perimenopausal and postmenopausa] women. Drugs Aging (2004) 21(13):865-883.
55. FOIDART JM: Added benefits of drospirenone for compliance. Climacteric (2005) 8(3):28-34.
56. SHULMAN LP, GOLDZIEHER JW: The truth about oral contraceptives and venous thromboembolism. J. Reprod. Med. (2003) 48(11 Suppl.):930-938.
57. SPITZER WO: Oral contraceptives and cardiovascular outcomes: cause or bias? Contraception (2000) 62(2 Suppl.):3S-9S; discussion 37S-38S.
58. FARMER RD, LAWERENSON RA, THOMPSON CR, KENNEDY JG, HAMBLETON IR: Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet (1997) 349(9045):83-88.
59. HEINEMANN LA, LEWIS MA, ASSMAN A, THIELC: Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception (2002) 65(3):207-214.
60. LAWRENSON R, FARMER R: Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference? Contraception (2000) 62(2 Suppl.):21S-28S; discussion 37S-38S.
61. LIDEGAARD O, EDSTROM B, KREINER S: Oral contraceptives and venous thromboembolsim: a five-year national case control study. Contraception (2002) 65(3):187-196.
62. SHELDON T: Dutch GPs warned against new contraceptive pill. Br. Med. J. (2002) 324(7342) 869.
63. VAN GROOTHEEST K, VRIELING T: Thromboembolism associated with the new contraceptive Yasmin. Br. Med. J. (2003) 326(7383):257.
64. DINGER JC, HEINEMANLA: European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903]. BMC Womens Health (2006) 6:1-7.
65. PEARCE HM, LAYTON D, WILTON LV et al.: Deep vein thrombosis and pulmonary embolism reported in the Prescription Even Monitoring Study of Yasmin. Br. J. Clin. Pharmacol. (2005) 60(1):98-102.
66. SCHURMANN R, BLODE H, BENDA N, CRONIN M, KUFNER A: Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal and impaired renal function. J. Clin. Pharmacol. (2006) 46(8):867-875.
67. PALACIOS S, FOIDART JM, GENAZZANI AR: Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas (2006) 55(4):297-307.
68. PRESTON RA, WHITE WB, PITT B et al.: Effects of drospirenone/ 17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am. J. Hypertens. (2005) 18(6):797-804.
69. IBANEZ L, DE ZEGHER F: Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third-to fourth-generation OC reduces body adiposity. Hum. Reprod. (1996) 19(8):1725-1727.
70. KROLL R, RAPKIN AJ: Treatment of premenstrual disorders. J. Reprod. Med. (2006) 51(4 Suppl):359-370.
71. YONKERS KA: The association between premenstrual dysphoric disorder and other mood disorders. J. Clin. Psychiatry (1997) 58(Suppl. n15):19-25.